Betamethasone Dipropionate

Summary

Betamethasone Dipropionate (CHEMBL1200384) is an approved small-molecule antipsoriatic; indicated across 10 conditions including psoriasis and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 10 conditions
• Clinical trials: 20
• Chemistry: 504.6 Da · C28H37FO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200384
Name	Betamethasone Dipropionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	21800
ChEBI	CHEBI:31276
Molecular formula	C28H37FO7
Molecular weight	504.6
InChIKey	CIWBQSYVNNPZIQ-XYWKZLDCSA-N

SMILES: CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate

ChEBI definition: A steroid ester that is betamethasone in which the hydroxy hydrogens at positions 17 and 21 are replaced by propanoyl groups. It is used in combination with calcipotriene hydrate, a synthetic vitamin D analogue, for the topical treatment of plaque psoriasis in adult patients.

Pharmacological roles (ChEBI): antipsoriatic.

Also known as: Alphatrex, Betamethasone (as dipropionate), Betamethasone dipropionate, Diprolene, Diprolene af, Diprosone, Diprospan, Maxivate, NSC-758415, Rinderon dp, SCH 11460, SCH-11460

Patent coverage: 3,553 distinct patent families (12,700 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Ferritin light chain, Glucocorticoid receptor, Progesterone receptor, D(2) dopamine receptor, Delta-type opioid receptor, Adenosine receptor A3, Glucocorticoid receptor, Nuclear receptor subfamily 1 group I member 2, Cruzipain.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P06536	8.28	IC50	5.25	nM	CHEMBL_ACT_931444
NR3C1	8	AC50	10	nM	CHEMBL_ACT_25175979
PGR	6.52	AC50	300	nM	CHEMBL_ACT_25223143
DRD2	6.11	AC50	770	nM	CHEMBL_ACT_25140480
NR1I2	5.62	AC50	2400	nM	CHEMBL_ACT_25224403

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
skin disorder	4	MONDO:0005093	EFO:0000701
periarthritis	3	MONDO:0006898	EFO:1001097
gout	3	MONDO:0005393	EFO:0004274
lichen planus, oral	2	MONDO:0043923	EFO:0008517
sinusitis	2	MONDO:0005961	EFO:0007486
atopic eczema	1	MONDO:0004980	EFO:0000274
oral submucous fibrosis	1	MONDO:0018166	EFO:1001818

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE4	5
PHASE3	4
PHASE1	3
Not specified	3
PHASE2	2
PHASE1/PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02858713	PHASE4	COMPLETED	Adherence in Topical Treatment of Psoriasis
NCT04555707	PHASE4	UNKNOWN	The Maintenance Effect of Enstilar Foam in Combination With Otezla
NCT05139875	PHASE4	COMPLETED	Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis
NCT05175001	PHASE4	UNKNOWN	Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain
NCT07242846	PHASE4	COMPLETED	EFFECT OF INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE AND BETAMETHASONE ON INTRAOCULAR PRESSURE
NCT05981118	PHASE2/PHASE3	ENROLLING_BY_INVITATION	Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
NCT01188928	PHASE3	COMPLETED	LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
NCT01422434	PHASE3	COMPLETED	LEO 90105 Ointment in Japanese Subjects With Psoriasis
NCT03331523	PHASE3	COMPLETED	To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
NCT05983445	PHASE3	COMPLETED	Safety & Efffficacy of Genakumab in Patients With Frequent Flares
NCT07256834	PHASE1/PHASE2	NOT_YET_RECRUITING	Comparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat.
NCT00910676	PHASE2	COMPLETED	Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
NCT03026478	PHASE2	UNKNOWN	Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
NCT06332612	PHASE1/PHASE2	COMPLETED	Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial
NCT02355639	PHASE1	COMPLETED	A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
NCT02973776	PHASE1	COMPLETED	Vasoconstriction Trial With LEO 90100 Aerosol Foam
NCT03758365	PHASE1	COMPLETED	Evaluation of the Vasoconstriction Properties of MC2-01 Cream
NCT00800293	Not specified	COMPLETED	Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams
NCT03119454	Not specified	COMPLETED	Corticoid-16 in Long Term When Administered Systemically in Patients in Routine Medical Practice
NCT03525522	Not specified	UNKNOWN	Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).